Home
overview
The identification of oligonucleotides through drug discovery has been proven to be an outstanding breakthrough for novel drug design and target validation. Coupled with the fact that the potential therapeutic applications of oligonucleotides are enormous, means that keeping fully up to date with the latest developments in this area is exceptionally important. So why not take the opportunity to fully explore this topic at SMi’s latest pharmaceuticals conference?

At ‘New Developments in Oligonucleotide Therapeutics’, which will take place on the 28th & 29th November at the Hatton, London, SMi has succeeded in bringing together the experts from within oligonucleotide research. These key speakers will offer valuable insight into the novel therapeutic use of oligonucleotides and the applications that are available now and will potentially be available in the future.

In just 2 days, this top-level forum will allow you to fully update yourself on the latest developments in oligonucleotide therapeutics and discuss the major issues involved in making your company even more profitable in this area. The conference will focus on the recent advances in the field and will discuss novel approaches to various therapeutic disorders.

There will also be excellent networking opportunities available, allowing you to discuss the main issues with colleagues from all over the world.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Michael Gait

Dr Michael Gait, Senior Staff Scientist and Group Leader, Medical Research Council

9:10 IMMUNOMODULATORY CpG OLIGONUCLEOTIDES

Dr Art Krieg

Dr Art Krieg, Chief Scientific Officer, Coley Pharmaceutical Group

  • The immune system has evolved to detect bacterial DNA by the presence of “CpG motifs”, which are rare in our own DNA
  • Particular types of immune cells such as dendritic cells, express a CpG receptor, called TLR-9
  • CpG DNA activates both arms of the immune system – the innate and the acquired
  • The pattern of immune activation induced by CpG DNA is very Th1-like, which is desirable for immunotherapy of cancer, allergy/asthma, and infectious diseases
  • In animals, CpG oligonucleotides have impressive activity for cancer immunotherapy, and for the treatment or prevention of allergies and infectious diseases
  • In humans, certain CpG oligonucleotides appear to be relatively well tolerated at doses that activate both innate and acquired immune responses
  • 9:40 IMMUNOMODULATORY OLIGONUCLEOTIDES

    Dr Sudhir Agrawal

    Dr Sudhir Agrawal, President & Chief Scientific Officer, Hybridon

  • Developing a new class of therapeutics
  • Understanding the difference between antisense and immune stimulation
  • Modifications to neutralise or enhance immune stimulation
  • Structure activity relationship of immunomodulatory oligos (IMO)
  • Use of IMOs as adjuvants for vaccines
  • Use of IMOs as therapeutic agent for cancer and infectious diseases

    Custom, designing IMOs for intended application

  • 10:20 EXPLOITING PNA TECHNOLOGY

    Dr Søren Kjærulff

    Dr Søren Kjærulff, Vice President, Biology & Chief Scientific Officer, Pantheco

  • Advantages of an ordinary peptide base
  • Ability to block mRNA translation
  • Effect of resistance to nucleases and proteases
  • PNA antisense applications
  • The breakthrough in the development of future antibacterial drugs
  • 11:00 Morning Coffee

    11:20 LNA (LOCKED NUCLEIC ACIDS)

    Leif Helth Jensen

    Leif Helth Jensen, President and Chief Executive Officer, Cureon

  • The properties of LNA
  • The benefits of highly increased thermal stability and improved selectivity
  • LNA in relation to antisense and target validation
  • Recent advances in LNA chemistry and application
  • The impact on tomorrows technologies
  • 12:00 DISCOVERY TO DRUGS USING INVERSE GENOMICS™ PLATFORM TECHNOLOGY

    Dr Tsvi Goldenberg

    Dr Tsvi Goldenberg, Chairman & Chief Executive Officer, Immusol

  • Benefits of Inverse Genomics™ technology
  • Broadly applicable to multiple disease systems
  • Unbiased coverage of entire genome
  • Allows for identification of targets that need only modulation for therapeutic effect
  • Identifies key regulating targets
  • 12:40 Lunch

    13:40 NOVEL NUCLEIC ACIDS-BASED (NAB™) TECHNOLOGIES FOR MOLECULAR DISCOVERY AND THERAPEUTICS

    Dr Kris Iyer

    Dr Kris Iyer, Vice President & Head, Discovery, Origenix Technologies

  • Engineer small molecules that mimic the specific and selective molecular recognition paradigm employed by nucleic acids and proteins
  • Technology innovation – combinatorial libraries, beaded libraries, structure-based drug design, and computational tools
  • Molecular discovery – high throughput screening and lead optimisation
  • Proof of concept – potent compounds against hepatitis B virus (HBV)
  • ORI-1001, against genital warts, in phase I clinical trials
  • 14:20 TARGETING BRAIN TUMOURS

    Dr Reimar Schlingensiepen

    Dr Reimar Schlingensiepen, Chief Operations Officer, ANTISENSE PHARMA

  • Targeting TGF-ƒÒƒnoligonucleotides
  • Mechanism of action
  • Results of clinical trials
  • Today¡¦s challenges, tomorrows goals
  • 15:00 THE EVOLUTION OF ANTISENSE THERAPEUTICS

    Dr Andrew Dorr

    Dr Andrew Dorr, Vice President & Chief Medical Officer, Isis Pharmaceuticals

  • Phosphorothioate oligodeoxynucleotide – phase I, II and III
  • New chemistries in the clinic
  • Novel formulations and delivery
  • 15:40 Afternoon Tea

    16:00 A NOVEL USE OF MIRROR IMAGE OLIGONUCLEOTIDES

    Dr Michael Courtney

    Dr Michael Courtney, Chief Scientific Officer, NOXXON Pharma

  • Mirror image aptamers
  • Mechanism of action
  • Advantages over other therapeutic treatments
  • The next step: pre-clinical trials
  • 16:30 RIBOZYMES: A PLATFORM TECHNOLOGY FOR THERAPEUTICS AND DIAGNOSTICS

    Dr Nassim Usman

    Dr Nassim Usman, Vice President, Research and Development, Ribozyme Pharmaceuticals

  • Mechanism of action
  • Better specificity and lower toxicity than antisense
  • Efficacy & clinical results
  • Allosteric ribozymes in diagnostics
  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Daniel O'Mahony

    Dr Daniel O'Mahony, Director, Biological Sciences, Elan Biotechnology Research

    9:10 DEVELOPMENT OF ANTISENSE THERAPEUTICS FOR ARTERIAL RESTENOSIS

    Dr Denis Burger

    Dr Denis Burger, Chairman & Chief Executive Officer, AVI BioPharma

  • Targeting the disease-causing gene sequence
  • Moving from phase I to phase II clinical trials
  • Early indications
  • The potential to control or eliminate cancer
  • The future challenges
  • Where to now
  • 9:40 TRANSCRIPTION FACTOR DECOY OLIGONUCLEOTIDES

    Dr Leslie McEvoy

    Dr Leslie McEvoy, Senior Director, Research, Corgentech

  • Targeting transcription factors to selectively modulate gene expression
  • Regulation of specific pathways for effective therapeutic benefit
  • Rapid validation of targets and decoys
  • Case study: E2F Decoy – designed to improve long term durability of bypass grafts · Mechanism of action · Proof-of-concept/preclinical studies · Phase II clinical trials
  • 10:20 INHIBITION OF DNA METHYLTRANSFERASE

    Donald Corcoran

    Donald Corcoran, President and Chief Executive Officer, MethylGene

  • Modifying gene expression as a therapeutic modality in cancer
  • Silencing DNA methyltransferase gene expression
  • MG98: Preclinical evidence
  • MG98: Clinical trials
  • The future outlook
  • 11:00 Morning Coffee

    11:20 USE OF RNAi FOR TARGET VALIDATION AND THERAPEUTICS

    Dr Tony Giordano

    Dr Tony Giordano, Director, Nucleonics

  • A background on the use of dsRNA to silence gene expression
  • dsRNA and the interferon response
  • Silencing of gene expression in mammalian cell cultures
  • Silencing of HIV infection in mammalian cell cultures
  • Post-transcriptional silencing of genes during zebra fish development
  • Post-transcriptional silencing in adult mice
  • 12:00 TARGET VALIDATION

    Dr Martin Ford

    Dr Martin Ford, Section Leader, High Throughput Biology, GlaxoSmithKline

  • The need for early evidence of disease association
  • Determining the function and therapeutic significance of gene targets
  • Antisense and RNAi as tools for target validation
  • The advantages over conventional approaches
  • Validating novel genes using antisense technology
  • Oligonucleotides as drugs for the clinic

    The challenges

  • 12:40 Lunch

    14:00 DRUG DELIVERY

    Dr Zeibun Ramtoola

    Dr Zeibun Ramtoola, Project Leader, Orasense, Elan Biotechnology Research

  • The main limitations to delivery of antisense
  • Routes of delivery of antisense, targeted, local, systems
  • Oral delivery of antisense
  • Product development, challenges and opportunities
  • 14:40 UNRAVELLING OF NOVEL SIGNALLING PATHWAYS

    Dr Klaus Giese

    Dr Klaus Giese, Vice President, Research, atugen

  • Case study: atugen’s technology platform
  • Addressing the two major bottlenecks in pharmaceutical research: · Target validation · Lead compound optimisation
  • Enabling discovery, validation and the selection of new drug targets
  • A straight forward, reversible and rapid technology
  • Application in vitro and in vivo
  • 15:20 PATENT ISSUES IN OLIGONUCLEOTIDE DRUG DEVELOPMENT

    John Caldwell

    John Caldwell, Partner, Woodcock Washburn Kurtz Mackiewicz & Norris

  • Current issues in genetic patenting
  • Patent exclusivity: how much protection is provided?
  • What strategies can be used to protect drug developments
  • Overcoming a competitor patent blockade
  • Making the most of your IP
  • 16:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.